Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.09. | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 5 | Investing.com | ||
11.09. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
10.09. | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
10.09. | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
10.09. | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
08.09. | Rapport Therapeutics launches $250 million public stock offering | 15 | Investing.com | ||
08.09. | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
08.09. | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 2 | Investing.com Deutsch | ||
08.09. | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com | ||
08.09. | Rapport Therapeutics Stock Rises To 117% After Positive Phase 2a Trial Results | 3 | RTTNews | ||
08.09. | TD Cowen bestätigt Kaufempfehlung für Rapport Therapeutics nach starken Studiendaten | 3 | Investing.com Deutsch | ||
08.09. | Rapport Therapeutics stock rating reiterated as Buy by TD Cowen | 16 | Investing.com | ||
08.09. | Rapport Therapeutics stock soars after positive Phase 2a seizure drug results | 13 | Investing.com | ||
08.09. | Rapport Therapeutics: Aktie springt nach positiven Phase-2a-Studienergebnissen um 160 % | 2 | Investing.com Deutsch | ||
08.09. | Rapport Therapeutics: Phase 2a Trial Of RAP-219 Meets Primary Endpoint | 1 | RTTNews | ||
08.09. | Rapport Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
08.09. | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | 267 | GlobeNewswire (Europe) | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
05.09. | Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset | 2 | Seeking Alpha | ||
05.09. | Rapport Therapeutics kündigt Vorstellung von Phase-2a-Studienergebnissen für Epilepsie-Medikament an | 9 | Investing.com Deutsch | ||
05.09. | Rapport Therapeutics to report phase 2a trial results for epilepsy drug | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,730 | +1,78 % | Von Abnehmspritzen bis Krebstherapie: Diese Plattform-Technologie greift gleich mehrere Milliardenmärkte an! | Anzeige / WerbungDie moderne Medizin steht vor einer gewaltigen Aufgabe: Immer mehr Menschen leiden an sogenannten Wohlstandserkrankungen wie Adipositas, Diabetes, Multiple Sklerose oder MASH, der gefürchteten... ► Artikel lesen | |
PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
VIKING THERAPEUTICS | 24,095 | +1,28 % | Viking Therapeutics: Bald wieder im Rampenlicht? | Die Aktionäre von Viking Therapeutics mussten zuletzt einen herben Kursrückgang verkraften, während ein potenzieller Konkurrent für eine hohe Milliardenbewertung übernommen wurde. Dabei gilt Viking... ► Artikel lesen | |
ABIVAX | 71,90 | +1,84 % | EQS-News: ABIVAX: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United... ► Artikel lesen | |
GERON | 1,211 | +3,20 % | British & American swings to interim loss, NAV falls on Geron slump | ||
CELLECTAR BIOSCIENCES | 5,850 | +0,52 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
GALAPAGOS NV | 31,580 | +3,61 % | Galapagos NV: Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business | Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement:
On May 13, 2025, Galapagos announced that its... ► Artikel lesen | |
CARDIFF ONCOLOGY | 1,782 | -0,34 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
CYTOKINETICS | 49,800 | +3,75 % | Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? | ||
CYTOMX THERAPEUTICS | 2,706 | -3,50 % | Why CytomX Therapeutics Stock Was Skyrocketing This Week | ||
FIBROGEN | 9,650 | -4,46 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
SPERO THERAPEUTICS | 1,590 | -7,99 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
MINERVA NEUROSCIENCES | 1,780 | -1,66 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
LISATA THERAPEUTICS | 2,100 | +6,06 % | Lisata Therapeutics, Inc.: Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial | Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29, 2025... ► Artikel lesen | |
ROIVANT SCIENCES | 13,630 | 0,00 % | Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy |